These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38895597)

  • 1. The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas.
    Offin M; Fitzgerald B; Zauderer MG; Doroshow D
    J Cancer Metastasis Treat; 2023; 9():. PubMed ID: 38895597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma.
    Li Y; Yang SR; Chen YB; Adusumilli PS; Bialik A; Bodd FM; Ladanyi M; Lopardo J; Offin MD; Rusch VW; Travis WD; Zauderer MG; Chang JC; Sauter JL
    Mod Pathol; 2023 Mar; 36(3):100030. PubMed ID: 36788094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library.
    Offin M; Sauter JL; Tischfield SE; Egger JV; Chavan S; Shah NS; Manoj P; Ventura K; Allaj V; de Stanchina E; Travis W; Ladanyi M; Rimner A; Rusch VW; Adusumilli PS; Poirier JT; Zauderer MG; Rudin CM; Sen T
    Genome Med; 2022 Nov; 14(1):127. PubMed ID: 36380343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of localized pleural mesothelioma.
    Hung YP; Dong F; Dubuc AM; Dal Cin P; Bueno R; Chirieac LR
    Mod Pathol; 2020 Feb; 33(2):271-280. PubMed ID: 31371807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma.
    Yun KM; Bazhenova L
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma.
    Paajanen J; Bueno R; De Rienzo A
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models of malignant mesothelioma.
    Kane AB
    Inhal Toxicol; 2006 Nov; 18(12):1001-4. PubMed ID: 16920675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma.
    Schaefer IM; Mariño-Enríquez A; Hammer MM; Padera RF; Sholl LM
    Mod Pathol; 2023 Sep; 36(9):100237. PubMed ID: 37295554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.
    Yang H; Hall SRR; Sun B; Zhao L; Gao Y; Schmid RA; Tan ST; Peng RW; Yao F
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.
    Perera ND; Mansfield AS
    Curr Oncol Rep; 2022 Nov; 24(11):1413-1423. PubMed ID: 35657483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of
    Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
    Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter study of diffuse pleural mesothelioma. Histopathological and immunohistochemical features.
    Poleri C; Acosta Haab G; Falcoff N; Guman G; Dalurzo L; Iotti A; Martín ME; Olmedo G; Rayá M; Reginatto A; Werbach A; Demelli G; Labanca MJ; Leguina L; Mora MF
    Medicina (B Aires); 2022; 82(2):210-216. PubMed ID: 35417384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mouse model recapitulating molecular features of human mesothelioma.
    Altomare DA; Vaslet CA; Skele KL; De Rienzo A; Devarajan K; Jhanwar SC; McClatchey AI; Kane AB; Testa JR
    Cancer Res; 2005 Sep; 65(18):8090-5. PubMed ID: 16166281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.
    Cunningham R; Jia S; Purohit K; Salem O; Hui NS; Lin Y; Carragher NO; Hansen CG
    Clin Transl Med; 2023 Feb; 13(2):e1190. PubMed ID: 36740402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy.
    Singh A; Pruett N; Dixit S; Gara SK; Wang H; Pahwa R; Schrump DS; Hoang CD
    J Exp Clin Cancer Res; 2023 Nov; 42(1):304. PubMed ID: 37974213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma.
    Kratzke RA; Otterson GA; Lincoln CE; Ewing S; Oie H; Geradts J; Kaye FJ
    J Natl Cancer Inst; 1995 Dec; 87(24):1870-5. PubMed ID: 7494231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features.
    Michal M; Kravtsov O; Ross JS; Skanderová D; Martínek P; Mosaieby E; Mata DA; Williams EA; Hung YP
    Genes Chromosomes Cancer; 2023 May; 62(5):267-274. PubMed ID: 36515470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapy in Mesotheliomas: Uphill All the Way.
    Bertoli E; De Carlo E; Bortolot M; Stanzione B; Del Conte A; Spina M; Bearz A
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Landscape of Malignant Mesotheliomas.
    Kato S; Tomson BN; Buys TP; Elkin SK; Carter JL; Kurzrock R
    Mol Cancer Ther; 2016 Oct; 15(10):2498-2507. PubMed ID: 27507853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.